Cost-Effectiveness Analysis of 177Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective.
Saved in:
| Title: | Cost-Effectiveness Analysis of 177Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective. |
|---|---|
| Authors: | Gogebakan KC; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington; kgogebak@fredhutch.org., Kunst N; Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale School of Medicine, New Haven,Connecticut., Ghodsi A; Division of Nuclear Medicine, Department of Radiology, University of Washington School of Medicine, Seattle, Washington; and., Owens L; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington., Iravani A; Division of Nuclear Medicine, Department of Radiology, University of Washington School of Medicine, Seattle, Washington; and.; Fred Hutchinson Cancer Center, Seattle, Washington., Etzioni R; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington. |
| Source: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2026 Jun 01; Vol. 67 (6), pp. 936-942. Date of Electronic Publication: 2026 Jun 01. |
| Publication Type: | Journal Article; Comparative Study |
| Journal Info: | Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
